Lytix Biopharma AS
F:6BG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of Lytix Biopharma AS (6BG) under the Base Case is 0.234 EUR per share. Compared with the current market price of 0.888 EUR, the stock appears Overvalued by 74% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Lytix Biopharma AS Does
Lytix Biopharma AS is a Norwegian biotechnology company that develops cancer medicines based on the body’s own immune system. Its core idea is to make tumor cells easier for the immune system to recognize and attack, rather than relying only on traditional chemotherapy or surgery. The company’s work centers on drug candidates designed for use in oncology, especially in tumors that are hard to treat with standard approaches.
- Headquarters
- Norway NO
- Employees
- 14
- IPO date
- Jun 14, 2021
Earnings Waterfall
Lytix Biopharma AS
What is the Intrinsic Value of one 6BG stock?
The intrinsic value for Lytix Biopharma AS (6BG) under the Base Case is 0.234 EUR.
Is 6BG stock undervalued or overvalued?
Compared with the current market price of 0.888 EUR, the stock appears Overvalued by 74% .